Lymphopenia association with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases

doi:10.21203/rs.3.rs-4282371/v1

Download PDF

Research Article

Lymphopenia association with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases

https://doi.org/10.21203/rs.3.rs-4282371/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Introduction: Radiotherapy has emerged as a primary treatment modality for brain metastases, and there is increasing awareness of its potential side effects, such as lymphopenia. Therefore, the objective of this study was to establish the association between WBRT and the development of lymphopenia in patients with brain metastases undergoing brain radiotherapy (RT), along with evaluating the corresponding clinical outcomes.

Methods: The study included a total of 116 patients with brain metastases undergoing brain radiotherapy, and collected the absolute lymphocyte count (ALC) within 2 weeks before brain radiotherapy (pre-radiotherapy, pre-RT), as well as at 1 and 2 months after completing RT (post-RT). Univariate and multivariate analyses were performed to identify associations between radiation modality and post-RT ALC. The relationships between post-RT ALC and overall survival were evaluated with Kaplan-Meier analysis and a multivariate Cox regression model.

Results: At 1 month post-RT, the median ALC definitely decreased. At 2 months post-RT, the ALC gradually rose but not to the pre-RT ALC. The multivariate analysis identified WBRT and lower pre-RT ALC as independent risk factors associated with the decrease in post-RT ALC at 1 month. It also revealed more than 4 brain metastases, G3-4 lymphopenia at 1 month and lower post-RT ALC at 2 months exhibited significantly worse prognosis regardless of the radiation modality. However, there is indeed an independent correlation between radiation modality and the outcome of intracranial progression-free survival (PFS).

Conclusions: To approach the feasibility and reasonableness of treatment, clinicians should carefully consider various factors to achieve long-term survival of patients.

radiation-induced lymphopenia

whole-brain radiotherapy

brain metastases

risk factor

prognosis

This study demonstrated that in patients with brain metastases receiving radiotherapy, post-radiotherapy lymphopenia was independently affected by pre-radiotherapy absolute lymphocyte counts and radiation modality，especially whole-brain radiotherapy increasing the incidence of lymphopenia. In addition, Grade 3-4 lymphopenia at 1 month post-radiotherapy and lower post-radiotherapy absolute lymphocyte counts at 2 months might be prognostic factors for worse survival.

The overall survival of solid cancer has significantly improved with the advancement of systemic treatments and the development of modern imaging technology, leading to an inevitable increase in the incidence of brain metastases. Brain metastases occur in approximately 20% of patients with extracranial tumors, primarily due to changes in microvascular anatomy that trap cancer emboli[1]. Depending on the location of intracranial mass lesions, metastatic encephalomata often present with various symptoms, including edema, hemorrhage, headache, projectile vomiting, and dysfunction in eloquent brain areas. Once brain metastases occur, the prognosis of these patients continues extremely poor.

In the era of immunotherapy, the regulation of immune function plays an increasingly crucial role in the treatment of solid cancers. Immunotherapy, with its unique mechanism compared to traditional chemotherapy, holds a promising prospect in various cancers, including melanoma and HER-2 positive breast cancer[2, 3]. However, the central nervous system, historically regarded as an immune-privileged organ[4], poses challenges for the effectiveness of immunotherapy in treating brain metastases.

Radiotherapy, as an effective and prompt treatment, exerts a profound impact on both primary and metastatic brain tumors, due to the promotion of immune system as well as the suppression of immunologic surveillance. Currently, local therapy, such as whole-brain radiotherapy (WBRT) and focal radiotherapy including stereotactic radiosurgery (SRS), are the primary treatments for patients with brain metastases[5]. However, WBRT and focal radiotherapy differ in radiation time, fractionated dose, and fractionations. Focal radiotherapy is primarily used for oligo-brain metastasis, allowing for hypofractionation and smaller radioactive dose, while WBRT is the standard treatment for patients with multiple brain metastases due to its effectiveness in palliation, widespread availability, and ease of delivery[6, 7]. Both of radiation modality can achieve local control and prevent the recurrence of brain metastases.

Lymphocytes in the circulating blood are of vital importance in mediating cellular immunity against tumor cells. They have also recently been identified as an essential biomarker for predicting the response to immunotherapy[8]. Unfortunately, lymphocytes are the most sensitive cells in the hematopoietic system when it comes to radiation. Radiotherapy with a dose of 1–2 Gy can significantly reduce the number of lymphocytes[9], and even a dose of 3 Gy can cause a 90% reduction[10]. The resulting lymphopenia induced by radiotherapy exacerbates the risk of disease progression and death, including opportunistic infections that can interrupt the radiotherapy regimen and reduce the anti-tumor immune response[11]. Multiple studies have shown a reduction in the ALC following radiation therapy in various extracranial and intracranial malignancies[12–15].

However, the dynamic changes in ALC and the underlying mechanisms in WBRT have not been thoroughly elucidated. It is believed that the larger radiation field in WBRT exposes more circulating cells to incidental radiation doses within the treatment area, leading to lymphopenia[16]. Previous studies have demonstrated that lymphopenia is correlated with clinical features such as gross tumor volume and age[17, 18]. Dosimetric parameters have also been used to investigate radiation-induced lymphopenia. Higher mean lung dose and longer treatment duration are significantly associated with lower post-SBRT ALC[19]. In glioma, whole-brain V20 is correlated with radiation-induced lymphopenia[20]. However, whether WBRT, which irradiates the entire brain tissue, is associated with radiation-induced lymphopenia in patients with brain metastases remains unknown. Despite increasing evidence regarding the impact of radiation-induced lymphopenia on poor survival in patients receiving extracranial radiotherapy[13, 18, 21], the prognosis of brain metastases patients developing radiation-induced lymphopenia through brain radiotherapy is still unclear.

This study aimed to investigate the influence of different radiation modalities on the changes in ALC among patients with brain metastases undergoing brain radiotherapy and evaluate its ultimate impact on survival.

Patient selection

A total of 116 patients with brain metastases who received brain radiotherapy at our institution between September 2019 and February 2022 were included in this study. The inclusion criteria were as follows (1) biopsy-confirmed diagnosis of extracranial solid tumor (including lung, breast, colon cancer, etc.) at either the primary site or metastatic lesion; (2) diagnosis of brain metastasis confirmed by enhanced magnetic resonance imaging (MRI); (3) no history of brain radiotherapy; (4) available detailed individual information (clinical features and radiotherapy regimens); (5) expected survival time of more than 3 months.

Treatments

After evaluating brain metastases by enhanced MRI, the radiation modality, either WBRT with or without local boost or focal radiotherapy was selected by clinicians based on individual difference. Available methods for brain radiotherapy included focal radiotherapy for limited metastases (≤ 4) and WBRT for multiple lesions (> 10). In most cases of metastatic brain tumors, the extracranial disease state and Eastern Cooperative Oncology Group (ECOG) score of patients with 4–10 metastatic lesions would influence the choice of radiation modality, except for small cell lung cancer (SCLC), where WBRT was recommended regardless of the number of brain metastases. Radiotherapy was delivered by intensity-modulated radiotherapy (IMRT) technique. The gross tumor volume of metastasis (GTVm) was defined as specific lesion on T2 FLAIR sequence, which was the referential safety margin by expanding 0.3 cm to generate planning target volume of metastasis (PTVm). Common organs at risk included brainstem, hippocampus, bilateral lens of eyes, optical nerves and chiasma, if necessary. The standard prescription dose of WBRT were 25 Gy in 10 fractions, 30 Gy in 10 fractions, and 37.5 Gy in 15 fractions. In some cases, an additional radiation boost was delivered for WBRT at a dose of 10–20 Gy in 5–10 fractions. And the dose of focal radiotherapy for intracranial lesions ranged from 54–60 Gy in 15–18 fractions. Of note, clinicians determined when it was appropriate to administer concurrent or sequential systemic therapies, including conventional cytotoxic chemotherapy, targeted therapy with or without immunotherapy, based on the tumor type and physical condition of the patient. However, the use of herbal medications was prohibited.

Assessment of lymphopenia

Peripheral venous blood samples were collected to measure ALC at three time points: within 2 weeks before the treatment (pre-RT), 1 month after completing brain radiotherapy (post-RT), and 2 months post-RT. The classic threshold for lymphopenia was defined as an absolute lymphocyte count < 1000 cells/µL. Lymphopenia was categorized according to Common Terminology Criteria for Adverse Events criteria (CTCAE), version 5.0, as Grade 1 (800–1000 cells/µL), Grade 2 (500–800 cells/µL), Grade 3 (200–500 cells/µL), and Grade 4 (< 200 cells/µL).

Statistical analysis

The statistical analysis was conducted using with the Statistical Package for Social Sciences, version 23.0 ( IBM SPSS Statistics, Chicago, IL, USA). A significance level of p ≤ 0.05 was used to determine statistical significance. The clinical and treatment characteristics were summarized using descriptive statistics. Univariate and multivariate linear regression analyses were performed to identify variables associated with post-RT ALC. Covariates with p ≤ 0.05 in the univariate analysis were incorporated in the multivariate model. Overall survival (OS) was determined as the time from the start of brain radiotherapy to the date of death from any cause or the last follow-up visit. The Kaplan-Meier estimator with a log-rank test was used to calculate and compare OS based on different covariates. Multivariate Cox regression was used to assess the impact of clinical factors and radiation modality on overall survival and intracranial PFS.

Patient characteristics

The study included 116 patients with brain metastases who met the criteria and had available laboratory values for review. The median age was 62 years (range, 19–80 years). 77 (66.4%) patients were over 60 years old. The median follow-up was 8.3 months (range, 2-29.3 months). Among the patients, 37 (31.9%) received WBRT with or without local boost, while 79 (68.1%) received focal radiotherapy. Detailed characteristics of all the patients can be found in Table 1.

Table 1

Baseline characteristics of all study patients.
Characteristic	No. Of patients (%)
Age (years)
< 60	77 (66.4)
≥ 60	39 (33.6)
Sex
Male	60 (51.7)
Female	56 (48.3)
ECOG score
0–2	96 (82.8)
3	20 (17.2)
Primary tumor
Pulmonary	64 (55.2)
Extra-pulmonary	52 (44.8)
History of extracranial RT
Yes	31(26.7)
No	85(73.2)
Numbers of brain metastases
≦ 4	77 (55.0)
> 4	39 (45.0)
Systemic therapy
Chemotherapy	53 (45.7)
Non-chemotherapy	63 (54.3)
Chemotherapy
WBRT	24(45.3)
Focal radiotherapy	29(54.7)
Steroid use
Yes	51 (44.0)
No	65 (56.0)
Radiation modality
WBRT with or without local boost	37 (31.9)
Focal radiotherapy	79 (68.1)
Per fractionation of WBRT (Gy)
2.5	11 (29.7)
3	26 (70.3)
Per fractionation of focal RT (Gy)
3	44 (55.7)
4	35 (44.3)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; WBRT, whole-brain radiotherapy.

Changes of ALC following brain radiotherapy

Figure 1 illustrates the changes in peripheral lymphocyte counts following brain radiotherapy. The median pre-RT ALC was 1100 cells/µL (range, 290–3500 cells/µL). At baseline, 53 patients (45.7%) had lymphopenia, and 8 patients (6.9%) had severe lymphopenia (G3-4 lymphopenia, ALC < 500 cells/µL). At 1 month post-RT, the median ALC of all patients was 830 cells/µL (range, 120–2970 cells/µL). Additionally, 77 (66.4%) patients developed into lymphopenia at this time point, and the proportion of patients with G3-4 lymphopenia was 16.4%. At 2 months post-RT, data on ALC was available for analysis in only 77 patients due to death or out-of-hospital follow-up. The median ALC was 950 cells/µL (range, 190–3520 cells/µL). Among these patients, 48 (62.3%) patients evolved into lymphopenia. 13 (16.9%) patients developed into G3-4 lymphopenia. Both the proportion of patients with G3-4 lymphopenia at 1 month and 2 months post-RT were higher compared to baseline (p = 0.016, p = 0.015, respectively) (Fig. 1A-C). The median decrease in ALC was 160 cells/µL at 1 month post-RT and 130 cells/µL at 2 months post-RT, respectively. The evaluation of whether chemotherapy induced lymphopenia showed no significant difference in the change of ALC at 1 month post-RT (p = 0.09) (Fig. 1D). However, it is worth noting that whole-brain radiotherapy (WBRT) resulted in a significant decrease at 1 month post-RT in ALC while focal RT did not (p ≤ 0.01) (Fig. 1E).

Association of post-RT ALC with clinical factors

Initially, there were no significant differences in pre-RT ALC based on sex, age, history of extracranial radiotherapy, or primary tumor site (all p > 0.05). In the univariate analysis, it was found that lower pre-RT ALC, WBRT, more than 4 brain metastases, and a history of previous extracranial radiotherapy were significantly associated with lower post-RT ALC at 1 month. After performing stepwise multivariate linear regression, which incorporated all significant parameters from the univariate analysis, it showed that lower pre-RT ALC (p < 0.001) and WBRT (p = 0.006) were independent risk factors for the decrease in ALC at 1-month post-RT. At 2 months post-RT, the univariate analysis revealed that lower post-RT ALC was significantly associated with WBRT, history of extracranial radiotherapy and lower pre-RT ALC. The number of brain metastases, however, did not show a significant association. In the multivariate analysis, only pre-RT ALC (p < 0.001) was the independent risk factor for ALC at 2 months post-RT. Notably, the effects of chemotherapy and steroid use during RT did not show statistical significance of ALC at 1 and 2 months post-RT. The results of univariate and multivariate linear regression analyses between clinical factors and post-RT ALC are shown in Table 2.

Table 2

Univariate and multivariate linear regression analyses between clinical characteristics and ALC at 1 month and 2 months post-RT.
	ALC at 1 month post-RT			ALC at 2 months post-RT
	RC	95%CI	p	RC	95%CI	p
Univariate analysis
Sex (female VS. male)	0.139	-0.047 to 0.325	0.14	0.072	-0.215 to 0.358	0.618
Age (< 60 VS. ≥60)	0.004	-0.165 to 0.172	0.966	0.055	-0.183 to 0.293	0.645
ECOG score	-0.001	-0.102 to 0.1	0.988	-0.019	-0.174 to 0.135	0.804
Pulmonary tumor (yes VS. no)	0.062	-0.153 to 0.278	0.567	0.155	-0.16 to 0.471	0.33
Chemotherapy (yes VS. no)	0.054	-0.113 to 0.22	0.524	-0.123	-0.359 to 0.114	0.305
Steroid use (yes VS. no)	0.125	-0.044 to 0.294	0.146	-0.163	-0.412 to 0.086	0.195
Metastases lesion ( ≦ 4 VS. >4)	-0.208	-0.425 to -0.071	0.006	0.048	-0.165 to 0.261	0.65
Pre-RT ALC	0.65	0.548 to 0.752	0.000	0.739	0.558 to 0.92	0.000
History of extracranial RT (yes VS. no)	0.244	0.064 to 0.424	0.008	0.404	0.144 to 0.664	0.003
Radiation modality (WBRT VS. focal RT)	0.327	0.172 to 0.482	0.000	0.412	0.193 to 0.63	0.000
Multivariate analysis
Pre-RT ALC	0.617	0.506 to 0.729	0.000	0.739	0.558 to 0.92	0.000
Radiation modality (WBRT VS. focal RT)	0.006	0.048 to 0.276	0.017

Abbreviation: ALC, absolute lymphocyte count; RC, Regression coefficient; CI, confidence interval.

Prognostic value of post-RT ALC

Survival analysis was conducted to assess the prognostic value of post-RT ALC for clinical outcome. Among the patients included in the study, 69 were alive at the end of the follow-up period. The median overall survival (OS) was 14.5 months, with a 1-year OS rate of 56.2% and a 2-year OS rate of 35.5%. As shown in Fig. 2A-B, there was no significant difference in survival between patients with ALC ≥ 1000 cells/µL and ALC < 1000 cells/µL (G1-4 lymphopenia) at either 1 month or 2 months after completing brain radiotherapy (p = 0.1 and p = 0.4, respectively). However, when comparing patients with ALC ≥ 500 cells/µL and ones with ALC < 500 cells/µL, clear differences in OS were observed at both 1 month and 2 months post-RT (p = 0.006 and p = 0.001, respectively) (Fig. 2C-D). Univariate analysis of clinical factors revealed that having more than 4 brain metastases (HR: 0.29; p < 0.001), pre-RT ALC (HR: 0.397; p = 0.009), ALC at 1-month and 2-month post-RT (HR: 0.417; p = 0.026; HR: 0.342; p = 0.031, respectively), and G3-4 lymphopenia at 1 month post-RT (HR: 0.408, p = 0.008) were associated with OS. In the multivariate analysis, after controlling for confounding variables including radiation modality, it was found that having more than 4 brain metastases (HR: 0.216; p < 0.001), G3-4 lymphopenia at 1-month post-RT (HR: 0.187; p = 0.008) and ALC at 2-month post-RT (HR: 0.049; p < 0.001) were significantly associated with shorter OS (Table 3). Additionally, Table 4 demonstrated that WBRT was an independent and significant predictor for intracranial PFS (p = 0.034).

Table 3

Univariate and multivariate Cox regression analysis of OS.
	Overall survival
	HR	95% CI	p
Univariate analysis
Sex (VS. female)	0.739	0.376–1.453	0.381
Age (VS. ≥60 y)	1.792	0.968–3.318	0.063
History of extracranial RT (VS. none)	1.476	0.794–2.743	0.218
Pulmonary tumor (VS. extrapulmonary tumor)	0.687	0.349–1.35	0.276
Chemotherapy (VS. none)	0.762	0.427–1.36	0.358
Steroid use (VS. none)	1.429	0.779–2.619	0.248
Metastases lesion ≦ 4 (VS. >4)	0.297	0.164–0.54	0.000
Pre-RT ALC	0.397	0.198–0.798	0.009
ALC at 1 month post-RT	0.417	0.193–0.901	0.026
ALC at 2 months post-RT	0.342	0.128–0.908	0.031
G3-4 lymphopenia (VS. G0-2) at 1 month post-RT	0.408	0.21–0.79	0.008
WBRT (VS. focal RT)	1.686	0.941–3.019	0.079
Multivariate analysis
Metastases lesion ≦ 4 (VS. >4)	0.216	0.095–0.493	0.000
G3-4 lymphopenia (VS. G0-2) at 1 month post-RT	0.187	0.054–0.642	0.008
ALC at 2 months post-RT	0.049	0.009–0.263	0.000

Abbreviations: HR, hazards ratio; G0-2 lymphopenia, Absolute lymphocyte count < 1000 cells/µL. G3-4 lymphopenia, Absolute lymphocyte count < 500 cells/µL.

Table 4

Cox regression analysis of intracranial PFS.
	OR	95% CI	p
ECOG score	0.935	0.232–3.769	0.925
Chemotherapy (VS. none)	1.378	0.116–16.428	0.800
Pre-RT ALC	0.002	0.000-5.416	0.121
ALC at 1 month post-RT	55.062	0.559-5427.085	0.087
WBRT (VS. focal RT)	42.114	1.325-1338.619	0.034
Metastases lesion ≦ 4 (VS. >4)	0.757	0.083–6.941	0.805
Per fractionation of RT	4.660	0.565–38.424	0.153
Baseline of ALC < 1	9.857	0.082-1189.622	0.349

In this study of patients with brain metastases receiving RT, we observed a significant decrease in ALC at 1 month after RT, followed by a gradual rebound at 2 months post-RT, but not reaching the pre-RT levels. Furthermore, WBRT and lower pre-RT ALC were significantly correlated with decreased post-RT ALC at 1 month after completing brain radiotherapy. However, only pre-RT ALC remained as an independent risk factor at 2 months post-RT. Moreover, the study confirmed that Grade 3–4 lymphopenia at 1 month post-RT and ALC at 2 months post-RT were independently associated with worse survival outcomes in a multivariate Cox model, while WBRT was independently associated with intracranial PFS.

Lymphocytes in the bone marrow may remain stationary during each fraction of RT, but they can move between fractions[22]. Despite the fact that the proliferating bone marrow in the skull accounts for only 6% of the total body marrow[23] and there is minimal lymphoid tissue in the brain and skull, there was a significant decrease in ALC at 1 and 2 months post-RT. And the actual amount of actively proliferating bone marrow within radioactive field predicted treatment-related lymphopenia[23]. Perhaps the exposure of circulating lymphocytes to radiation should be considered a significant factor in inducing lymphopenia[24]. These indicated that WBRT is more likely to induce lymphopenia compared to focal radiotherapy in the treatment of brain metastases. Previous studies have confirmed that WBRT leads to significant morbidity in terms of neurocognitive dysfunction and reduced quality of life[1]. And the influence on cognitive function of hippocampus sparing was inferior to conventional WBRT, which might need memantine to relieve its side effect[1]. However, WBRT-related lymphopenia had rarely been reported. Potential mechanisms may involve the following aspects. WBRT had larger radiation field than focal radiotherapy and brain tissue has rich blood flow, which contribute to the exposure and depletion of peripheral lymphocytes within radiation fields. In contrast, focal radiotherapy specifically targets localized intracranial lesions. Due to variations in techniques and beam arrangements, different levels of low and moderate radiation doses may be delivered to the vasculature outside the radiation field of the brain, which could also contribute to the exposure of circulating lymphocytes to radiation[25]. Furthermore, previous studies have demonstrated that dosimetric parameters, including gross tumor volume, lung V5, heart V5, integral body dose, and mean spleen dose, etc[11, 12, 15], had associated with radiation-induced lymphopenia in extracranial radiotherapy[26]. Thus, it is imperative to further investigate the relationships between dosimetric parameters and the decrease in ALC following brain radiotherapy in future studies. Presently, WBRT is regarded as the standard treatment for patients with more than 10 brain metastases. However, there is controversy regarding the use of WBRT for 4–10 brain metastases[27]. Therefore, considering its effects on PFS and lymphopenia, a comprehensive evaluation should be conducted when deciding whether to use WBRT for controlling brain metastases.

The dynamics of lymphocyte after extracranial radiotherapy have been extensively investigated. In one aspect, the white blood cell and platelet counts increased following a decline during RT, while ALC continuously decreased[28]. In another aspect, ALC gradually normalized over a period of 2 months after completing concurrent chemoradiotherapy in locally advanced pancreatic cancer[29]. According to Cho et al., the majority of patients experienced recovery from treatment-related lymphopenia at 3 months after radiotherapy[30]. Pike et al. found that lymphopenia after radiotherapy lasts for at least 6 months in cases of metastatic cancer[31]. It may take 1 year for the complete white cell series to reach a recovery plateau, while lymphocytes might require 6 years[24]. Further analysis revealed that the duration of radiation, age, and baseline ALC were associated with the recovery of lymphopenia[32]. Our study suggested that only pre-RT ALC was associated with ALC at 2 months post-RT, indicating the recovery process of lymphocytes uncorrelated to clinical factors but to the baseline of ALC before RT. However, further confirmation is required by expanding the sample size. Regarding symptomatic metastases and the mitigation of brain edema, steroid use often lasted for several days. Dexamethasone was lymphotoxic[25] and increased the incidence of lymphopenia[11]. However, our study demonstrated that steroid use during radiotherapy was not associated with ALC after completing brain radiotherapy when considering other clinical factors, which is consistent with prior data[33]. The main reason for the diverse results may be the short duration and low dosage. Moreover, numerous studies have demonstrated the effects of systemic therapy on the lymphocyte counts, including chemotherapy-induced decline in circulating lymphocytes, in addition to the evident inhibition of neutrophils. Sanchez-Pere et al. found that fist-line chemotherapy for glioblastoma often resulted in lymphopenia[34]. Chen et al. showed that patients with breast cancer might experience lymphopenia as a result of previous chemotherapy[35]. It is well known that myelosuppression is the most common adverse reaction of chemotherapy, leading to a decrease in white blood cells and neutrophils, which, to some extent, affects lymphocyte count. However, chemotherapy did not impact lymphocyte count in our study, possibly due to the small number of patients receiving chemotherapy (24 in WBRT and 29 in focal RT, respectively) and the poor ECOG scores of patients undergoing WBRT. Therefore, when selecting chemotherapy regimens, oncologists should likewise be considerate as much as possible in order to improve patients’ tolerance, particularly when combined with brain radiotherapy. Furthermore, target therapy and immunotherapy are less likely to impact lymphocyte count. The reasons for the discrepancy between our research and previous studies may be attributed to the relatively small sample size and other factors.

Prognostic factors in patients with brain metastases had been gradually identified. Performance status, evidence of systemic disease may be the strongest factors for prognosis[36]. Graded Prognostic Assessment was an important prognostic factor for lung cancer patients with brain metastases[37]. Currently, the relationship between ALC and clinical outcomes has been widely studied. Lymphopenia after treatment has been associated with decreased survival in patients with limited-stage small cell lung cancer[38]. Shiraishi et al. reported lymphopenia in 480 patients receiving neoadjuvant chemoradiotherapy and found that Grade 4 ALC was significantly associated with reduced distant metastasis-free surivival[39]. Our results showed that patients with G3-4 (lymphocyte count < 500 cells/µL) lymphopenia had worse survival compared with G0-2 lymphopenia at 1 month and 2 months post-RT, respectively. In the multivariate Cox model, including confounders such as the history of extracranial radiotherapy, radiotherapy modality, chemotherapy and steroid use, poor OS was related not only to G3-4 lymphopenia at 1 month post-RT but also to a lower ALC at 2 months post-RT. To the best of our knowledge, this study is the first to demonstrate an association between radiation-induced lymphopenia and prognosis in patients with brain metastases receiving radiotherapy. Previous reports have shown that radiation-induced lymphopenia affects the effectiveness of immunotherapy. Studies had demonstrated that a lower lymphocyte count could indicate diminished performance status and worse systemic immunity[40, 41]. Additionally, it has been observed that immune cells home to cancer and change its microenvironment through calreticulin and high-mobility group box 1 (HMGB 1)[11]. Finally, a worse effect of comprehensive treatment results in shorter intracranial PFS and poor overall survival. However, neither radiation modality nor the number of brain metastases showed a prominent relation with survival in either univariate or multivariate analysis. However, WBRT was associated with intracranial PFS (i. e. short-term efficacy). This might be attributed to the fact that most of the enrolled patients have received multi-line systemic treatments. Broadly speaking, the final survival of patients mainly depends on the efficacy of comprehensive treatments, tumor characteristics and patient’s condition. Reserving lymphocytes could potentially boost the response to systemic therapy[42]. For instance, keeping low dose of organs at risk can reduce the incidence of lymphopenia[22]. Clinicians should strive to strike a balance between better cancer control and the risk of lymphopenia. By avoiding or alleviating adverse effects as much as possible, therapeutic effectiveness can be enhanced and survival can be extended.

This study has some limitations. First, it was a retrospective study conducted at a single center with a limited number of cases, so selection bias was inevitable. Second, there is a need for further analysis of the dosimetric parameters related to radiation-induced lymphopenia. Third, for cases of limited brain metastases, focal radiotherapy was performed in our institution, but the prescribed dose of radiation and number of fractionations varied considerably from individual to individual, which might yield different results if replaced with standard radiation regimens. Therefore, further validation is required in the future studies.

We demonstrated that the reasonable selection of radiation modality can indirectly impact clinical outcomes by attenuating lymphopenia in patients undergoing brain radiotherapy. This finding suggests that in the era of precise treatments, taking into account individual differences, prognostic stratification is important for guiding clinicians in offering prudent and appropriate treatments to patients with risk factors, particularly those with 4–10 metastases of brain. Needless to say, completing radiotherapy of metastatic lesion without severe toxicities and complications, marks a profound impact on comprehensive therapy of solid tumors. Clinicians still have a long way to go to reach the final goal, but achieving some milestones remains well within the realm of possibility.

RT: radiotherapy;

ALC: absolute lymphocyte count;

Pre-RT: before brain radiotherapy;

Post-RT: after completing RT;

ECOG: Eastern Cooperative Oncology Group;

WBRT: whole-brain radiotherapy;

PFS: progression-free survival,;

SRS: stereotactic radiosurgery

GTVm: gross tumor volume of metastasis;

PTVm: planning target volume of metastasis;

CTCAE: Common Terminology Criteria for Adverse Events criteria

OS: overall survival.

Data availability and method statement

The original data presented in the study are included in the article. Further inquiries can be directed to the corresponding authors. All methods were carried out in accordance with relevant guidelines and regulations.

Ethics approval and consent to participate

This study was approved by the ethics committee of the second affiliated hospital of Chongqing medical university. The informed consent was obtained from all the patients. All methods were carried out in accordance with relevant guidelines and regulations.

Author contributions

Y Wang, WW Zeng collected data and wrote the manuscript. WY Xie and W Zhao designed the project and implemented the research. GP Yang collected and analysed data. YH Chen were responsible for patient follow-up. All authors contributed to the article and approved the submitted version.

Y Wang and WW Zeng contributed equally to the study.

Consent for publication

Not applicable.

Conflict of interest statement

The authors declare that they have no competing interests.

Acknowledgements and Funding

The study was supported by Chongqing Medical Scientific Research Project (No. 2020FYYX143) and the Natural Science Foundation of Chongqing, China (No. CSTB2023NSCQ-MSX020).

Brenner AW, Patel AJ: Review of Current Principles of the Diagnosis and Management of Brain Metastases. Front Oncol 2022, 12:857622.
Liu L, Chen W, Zhang R, Wang Y, Liu P, Lian X, Zhang F, Wang Y, Ma W: Radiotherapy in combination with systemic therapies for brain metastases: current status and progress. Cancer biology & medicine 2020, 17(4):910-922.
Schlam I, Gatti-Mays ME: Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases. The oncologist 2022, 27(7):538-547.
Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C et al: Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. Journal for immunotherapy of cancer 2022, 10(7).
Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS et al: Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-oncology 2017, 19(2):162-174.
Tonse R, Tom MC, Mehta MP, Ahluwalia MS, Kotecha R: Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. Cancers 2021, 13(15).
Singh R, Didwania P, Lehrer EJ, Palmer JD, Trifiletti DM, Sheehan JP: Repeat stereotactic radiosurgery for locally recurrent brain metastases previously treated with stereotactic radiosurgery: A systematic review and meta-analysis of efficacy and safety. Journal of radiosurgery and SBRT 2022, 8(1):1-10.
Cho Y, Park S, Byun HK, Lee CG, Cho J, Hong MH, Kim HR, Cho BC, Kim S, Park J et al: Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics 2019, 105(5):1065-1073.
Nakamura N, Kusunoki Y, Akiyama M: Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiation research 1990, 123(2):224-227.
Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. 2019, 135:115-119.
Upadhyay R, Venkatesulu BP, Giridhar P, Kim BK, Sharma A, Elghazawy H, Dhanireddy B, Elumalai T, Mallick S, Harkenrider M: Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2021, 157:225-233.
Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW: Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. International journal of radiation oncology, biology, physics 2014, 89(5):1084-1091.
Rudra S, Hui C, Rao YJ, Samson P, Lin AJ, Chang X, Tsien C, Fergus S, Mullen D, Yang D et al: Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. International journal of radiation oncology, biology, physics 2018, 101(1):217-225.
Kroese TE, Jairam J, Ruurda JP, Lin SH, Mohan R, Mook S, Haitjema S, Hoefer I, Haj Mohammad N, Peters M et al: Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2021, 163:192-198.
Liu J, Zhao Q, Deng W, Lu J, Xu X, Wang R, Li X, Yue J: Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. Radiation oncology (London, England) 2017, 12(1):90.
Xie X, Gong S, Jin H, Yang P, Xu T, Cai Y, Guo C, Zhang R, Lou F, Yang W et al: Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count. Radiation oncology (London, England) 2020, 15(1):65.
Xie X, Lin SH, Welsh JW, Wei X, Jin H, Mohan R, Liao Z, Xu T: Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2021, 154:187-193.
Taguchi A, Furusawa A, Ito K, Nakajima Y, Shimizuguchi T, Hara K, Takao M, Kashiyama T, Kino N, Karasawa K et al: Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study. International journal of clinical oncology 2020, 25(5):955-962.
Zhao Q, Li T, Chen G, Zeng Z, He J: Prognosis and Risk Factors of Radiation-Induced Lymphopenia in Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. Front Oncol 2019, 9:1488.
Byun HK, Kim N, Yoon HI, Kang SG, Kim SH, Cho J, Baek JG, Chang JH, Suh CO: Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiation oncology (London, England) 2019, 14(1):51.
Yu H, Chen F, Lam KO, Yang L, Wang Y, Jin JY, Ei Helali A, Kong FS: Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach. Front Immunol 2022, 13:768811.
Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, van Herk M: Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020, 15(10):1624-1635.
Park S, Byun HK, Seong J: Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma. Liver cancer 2019, 8(6):468-479.
Harisiadis L, Kopelson G, Chang CH: Lymphopenia caused by cranial irradiation in children receiving craniospinal radiotherapy. Cancer 1977, 40(3):1102-1108.
Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR et al: Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. International journal of radiation oncology, biology, physics 2015, 92(5):1000-1007.
Chen F, Jin JY, Hui TSK, Jing H, Zhang H, Nong Y, Han Y, Wang W, Ma L, Yi F et al: Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer. Front Oncol 2022, 12:768956.
Loo M, Clavier JB, Attal Khalifa J, Moyal E, Khalifa J: Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review. Cancers 2021, 13(23).
Yang TJ, Oh JH, Apte A, Son CH, Deasy JO, Goodman KA: Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2014, 113(1):29-34.
Lee BM, Byun HK, Seong J: Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2020, 151:82-87.
Cho Y, Kim Y, Chamseddine I, Lee WH, Kim HR, Lee IJ, Hong MH, Cho BC, Lee CG, Cho S et al: Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2022, 168:1-7.
Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O et al: The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. International journal of radiation oncology, biology, physics 2019, 103(1):142-151.
Zhao Q, Li T, Du S, He J, Zeng Z: Shortened Radiation Time Promotes Recovery From Radiation-induced Lymphopenia in Early-Stage Non-small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Technology in cancer research & treatment 2022, 21:15330338221112287.
Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S: Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clinical cancer research : an official journal of the American Association for Cancer Research 2011, 17(16):5473-5480.
Sanchez-Perez L, Suryadevara CM, Choi BD, Reap EA, Sampson JH: Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology 2014, 3(7):e944054.
Chen F, Ma L, Wang Q, Zhou M, Nong Y, Jing H, Han Y, Liu Y, Hu Y, Yu H et al: Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. Cancer reports (Hoboken, NJ) 2022, 5(7):e1525.
Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. International journal of radiation oncology, biology, physics 1999, 43(4):795-803.
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. International journal of radiation oncology, biology, physics 1997, 37(4):745-751.
Wang X, Lu J, Teng F, Yu J: Lymphopenia association with accelerated hyperfractionation and its effects on limited-stage small cell lung cancer patients' clinical outcomes. Annals of translational medicine 2019, 7(16):385.
Wang X, Wang P, Zhao Z, Mao Q, Yu J, Li M: A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. Therapeutic advances in medical oncology 2020, 12:1758835920926822.
Raghu D, Xue HH, Mielke LA: Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1. Trends in immunology 2019, 40(12):1149-1162.
Uzhachenko RV, Shanker A: CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Front Immunol 2019, 10:1906.
Chen D, Patel RR, Verma V, Ramapriyan R, Barsoumian HB, Cortez MA, Welsh JW: Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2020, 150:114-120.

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

Lymphopenia association with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases

Status:

Version 1

Abstract

Figures

Précis

Introduction

Materials and methods

Patient selection

Treatments

Assessment of lymphopenia

Statistical analysis

Results

Patient characteristics

Changes of ALC following brain radiotherapy

Association of post-RT ALC with clinical factors

Prognostic value of post-RT ALC

Discussion

Conclusion

Abbreviations

Declarations

References

Additional Declarations

Status:

Version 1